Evidence map›Paper›PMID 38057852›Full record

ArticleJournal of translational medicine2023

Silencing HOXC13 exerts anti-prostate cancer effects by inducing DNA damage and activating cGAS/STING/IRF3 pathway.

Maozhang Li, Guangwei Bai, Yi Cen, Qitong Xie, Jiahong Chen, Jia Chen, Qingbiao Chen, Weide Zhong, Xiaobo Zhou

Open access · goldAbstract read
In one paragraph

Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 18 citations in OpenAlex.

  1. [A multi-level study of androgen deprivation therapy on the immune microenvironment in prostate cancer].Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences · 2026
    Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Therapeutic Effect ofDrug design, development and therapy · 2025
    Article
  13. Article
  14. Loss of STING impairs lactogenic differentiation.Development (Cambridge, England) · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Maozhang Li *School of Medicine, Jinan University, Guangzhou, 510632, Guangdong, China.
Guangwei Bai *Department of Urology, Huizhou Municipal Central Hospital, Huizhou, 516001, China.
Yi Cen *Guangdong Provincial Key Laboratory of Molecular Target & Clinical Pharmacology, the NMPA and State Key Laboratory of Respiratory Disease, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
Qitong XieDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou, 516001, China.
Jiahong ChenDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou, 516001, China.
Jia ChenDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou, 516001, China.
Qingbiao ChenDepartment of Urology, The Second People's Hospital of Foshan, Affiliated Foshan Hospital of Southern Medical University, Foshan, 528000, China.
Weide ZhongSchool of Medicine, Jinan University, Guangzhou, 510632, Guangdong, China. zhongwd2009@live.cn.ORCID 0000-0002-0430-2845
Xiaobo ZhouDepartment of Urology, Huizhou Municipal Central Hospital, Huizhou, 516001, China. 13829969092@139.com.
Huizhou Central People's Hospital · CNJinan University · CNFoshan Second People's Hospital · CNState Key Laboratory of Respiratory Disease · CN

Funding

Guangdong Medical Science and Technology Research Fund Project of China B2020127Guangdong Medical Science and Technology Research Fund Project of China B2022332Guangdong Medical Science and Technology Research Fund Project of China B2023213Natural Science Foundation of Guangdong Province, China 2021A1515011088Natural Science Foundation of Guangdong Province, China 2021A1515012106
6 · The paper itself

Abstract

backgroundAdvanced prostate cancer (PCa) will develop into castration-resistant prostate cancer (CRPC) and lead to poor prognosis. As the primary subtype of CRPC, CRPC-AR accounts for the major induction of PCa heterogeneity. CRPC-AR is mainly driven by 25 transcription factors (TFs), which we speculate may be the key factors driving PCa toward CRPC. Therefore, it is necessary to clarify the key regulator and its molecular mechanism mediating PCa progression.

methodsFirstly, we downloaded transcriptomic data and clinical information from TCGA-PRAD. The characteristic gene cluster was identified by PPI clustering, GO enrichment, co-expression correlation and clinical feature analyses for 25 TFs. Then, the effects of 25 TFs expression on prognosis of PCa patients was analyzed using univariate Cox regression, and the target gene was identified. The expression properties of the target gene in PCa tissues were verified using tissue microarray. Meanwhile, the related mechanistic pathway of the target gene was mined based on its function. Next, the target gene was silenced by small interfering RNAs (siRNAs) for cellular function and mechanistic pathway validation. Finally, CIBERSORT algorithm was used to analyze the infiltration levels of 22 immune cells in PCa patients with low and high expression of target gene, and validated by assaying the expression of related immunomodulatory factor.

resultsWe found that HOX family existed independently in 25 TFs, among which HOXC10, HOXC12 and HOXC13 had unique clinical features and the PCa patients with high HOXC13 expression had the worst prognosis. In addition, HOXC13 was highly expressed in tumor tissues and correlated with Gleason score and pathological grade. In vitro experiments demonstrated that silencing HOXC13 inhibited 22RV1 and DU145 cell function by inducing cellular DNA damage and activating cGAS/STING/IRF3 pathway. Immune infiltration analysis revealed that high HOXC13 expression suppressed infiltration of γδ T cells and plasma cells and recruited M2 macrophages. Consistent with these results, silencing HOXC13 up-regulated the transcriptional expression of IFN-β, CCL2, CCL5 and CXCL10.

conclusionHOXC13 regulates PCa progression by mediating the DNA damage-induced cGAS/STING/IRF3 pathway and remodels TIME through regulation of the transcription of the immune factors IFN-β, CCL2, CCL5 and CXCL10.

Indexed as

Prostatic Neoplasms, Castration-ResistantDNA DamageGene Expression Regulation, NeoplasticHomeodomain ProteinsHumansInterferon Regulatory Factor-3MaleNucleotidyltransferasesTranscription FactorsHomeodomain ProteinsHOXC10 protein, humanHOXC13 protein, humanInterferon Regulatory Factor-3IRF3 protein, humanNucleotidyltransferasesTranscription FactorscGAS/STING/IRF3 pathwayHOXC13IFN-βImmune infiltrationProstate cancer

Identifiers

PMID38057852
PMCPMC10701956
OpenAlexW4389380971

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.